|Issue 1188: June 16, 2015
Ask the Experts—Question of the Week: An 8-year-old child received three doses of oral polio vaccine before his first birthday…read more
OFFICIAL RELEASES AND ANNOUNCEMENTS
JOURNAL ARTICLES AND NEWSLETTERS
EDUCATION AND TRAINING
CONFERENCES AND MEETINGS
Reminder: May issues of Needle Tips and Vaccinate Adults available online
The May 2015 issues of Needle Tips and Vaccinate Adults are available online. Vaccinate Adults is an abbreviated version of Needle Tips with the pediatric content removed.
Click on the images below to download the entire May issues (PDF) of Needle Tips and/or Vaccinate Adults.
Needle Tips: View the table of contents, magazine viewer, and back issues.
Vaccinate Adults: View the table of contents, magazine viewer, and back issues.
If you would like to receive immediate email notification whenever new issues of Needle Tips or Vaccinate Adults are released, visit IAC's subscribe page to sign up.
Back to top
ACIP publishes recommendations for use of serogroup B meningococcal vaccines in people age ten years and older at increased risk for serogroup B meningococcal disease
CDC published Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015 in the June 12 issue of MMWR (pages 608–612). The first paragraph and the sections titled "Rationale for Recommendations" and "Recommendations" are reprinted below.
In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.]) as a 3-dose series. In January 2015, FDA licensed a second MenB vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose series. Both vaccines were approved for use in persons aged 10–25 years. Following outbreaks of serogroup B meningococcal disease on two college campuses in 2013, both MenB vaccines were granted Breakthrough Therapy designations, which expedites drug development and review by FDA, and were licensed based on accelerated approval regulations. On February 26, 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease. This report summarizes information on MenB administration and provides recommendations and guidance for use of these vaccines among persons aged ≥10 years in certain groups who are at increased risk for serogroup B meningococcal disease, and reviews the evidence considered by ACIP to make these recommendations. Recommendations for broader use of MenB vaccines in adolescents and college students will be considered separately by ACIP.
Rationale for Recommendations
Certain groups of persons known to be at increased risk for meningococcal disease are recommended to be routinely vaccinated with a quadrivalent meningococcal conjugate vaccine (MenACWY), which protects against serogroups A, C, W, and Y. Many of these groups are also at increased risk for serogroup B meningococcal disease. Available immunogenicity and safety data support the use of MenB vaccines in groups at increased risk for serogroup B meningococcal disease.
Both MenB vaccines are approved for use in persons aged 10–25 years; however, because there are no theoretical differences in safety for persons aged >25 years compared with those aged 10–25 years, ACIP supported routine use of MenB vaccines in persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease. These recommendations do not apply to children aged <10 years.
Certain persons aged ≥10 years who are at increased risk for meningococcal disease should receive MenB vaccine. These persons include:
MenB vaccine should be administered as either a 2-dose series of MenB-4C or a 3-dose series of MenB-FHbp. The same vaccine product should be used for all doses. Based on available data and expert opinion, MenB-4C or MenB-FHbp may be administered concomitantly with MenACWY vaccines, but at a different anatomic site, if feasible.
American Medical Association adopts new policy that supports ending non-medical vaccine exemptions, including those for healthcare professionals
At its annual meeting in June, the American Medical Association (AMA) adopted a new policy that supports ending non-medical exemptions to immunization mandates. An AMA press release from June 8 is reprinted below.
Addressing the re-emergence of vaccine-preventable diseases in the United States requires states to move toward barring non-medical exemptions to immunization mandates, according to new policy adopted by the nation's physicians at the American Medical Association's annual meeting. Under new policy, the AMA will seek more stringent state immunization requirements to allow exemptions only for medical reasons.
Immunization programs in the Unites States are credited with having controlled or eliminated the spread of epidemic diseases, including smallpox, measles, mumps, rubella, diphtheria and polio. Immunization requirements vary from state to state, but only two states bar non-medical exemptions based on personal beliefs.
"When people are immunized, they also help prevent the spread of disease to others, said AMA Board Member Patrice A. Harris, MD. "As evident from the recent measles outbreak at Disneyland, protecting community health in today's mobile society requires that policymakers not permit individuals from opting out of immunization solely as a matter of personal preference or convenience."
New AMA policy recommends that states have in place an established decision mechanism that involves qualified public health physicians to determine which vaccines will be mandatory for admission to schools and other public venues. States should only grant exemptions to these mandated vaccines for medical reasons.
In recognition that highly transmissible diseases could pose significant medical risks for vulnerable patients and the health care workforce, new AMA policy also states that physicians and other health professionals who have direct patient care responsibilities have an obligation to accept immunization unless there is a recognized medical reason.
The AMA also intends to support the dissemination of materials on vaccine efficacy to states as part of the effort to eliminate non-medical exemptions.
CDC reports on serogroup B meningococcal disease outbreak and carriage evaluation at a college
CDC published Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College—Rhode Island, 2015 in the June 12 issue of MMWR (pages 606–607). A summary made available to the press is reprinted below.
In response to a serogroup B meningococcal disease outbreak at a college in Rhode Island, targeted antibiotic chemoprophylaxis of close contacts and a mass vaccination campaign with a recently-licensed serogroup B meningococcal (MenB) vaccine were implemented. No further cases have been identified. Additionally, an evaluation of asymptomatic nasopharyngeal carriage of Neisseria meningitidis, the bacteria that causes meningococcal disease, found that 25 percent of the 717 student participants carried N. meningitidis, 4 percent specifically carried serogroup B, and none carried the outbreak strain. This baseline carriage prevalence is higher than previous U.S. estimates of 1 percent to 8 percent among the general population, but is comparable to prevalences observed in United Kingdom university students. Two additional carriage evaluations will assess MenB vaccination impact on carriage over time in this college population.
Back to top
IAC Spotlight! Vaccine Information Statements in up to 40 languages are ready for your use
If you provide vaccination services for people who don’t speak or read English, the Immunization Action Coalition (IAC) is the “go-to” place for translations of Vaccine Information Statements (VISs). For more than 15 years, IAC has made VIS translations available on immunize.org. In 2011, IAC entered into a cooperative agreement with the Centers for Disease Control and Prevention (CDC) to establish IAC’s role as the official source of VIS translations.
For the 18 languages listed below, IAC has up-to-date VIS translations for all routinely recommended vaccines. You can download all translations in a particular language from the links listed below:
Thanks to IAC’s Partners Who Provide Translations
Many of the VISs available on immunize.org are donated to IAC by generous partners. We count on our partners to provide translation services every time new or updated VISs are released by CDC and are deeply grateful to the following organizations and individuals for their time and dedication to providing VIS translations: Arkansas Department of Health; Asian Pacific Health Care Venture, Los Angeles, CA; California Department of Public Health; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases; DSMA Ethiopian Orthodox Church, Minneapolis, MN; Family Medicine Health Center, Refugee Screening Clinic, Boise, ID; Hawaii Department of Health; Healthy Roads Media, Falcon Heights, MN; Mustafa Kozanolgu, MD, Toronto, Canada; Massachusetts Department of Health and Human Services; Minnesota Department of Health; New York City Department of Health and Mental Hygiene; St. Peter’s Health Partners, Albany, NY; Don Shuwarger, MD, FACOP, MBA, Alamogordo, NM; Swedish Medical Center, Seattle, WA; and Wentworth Douglass Hospital, Dover, NH.
Would you like to donate translations for IAC?
If you are interested in becoming a translation partner of IAC, please visit www.immunize.org/translate.asp to find out details about how it works. Contact us at firstname.lastname@example.org, if you would like additional information.
Back to top
Reminder: 13th edition of CDC's "Pink Book" now available to order or download
CDC has just released the 13th edition of its book, Epidemiology and Prevention of Vaccine-Preventable Diseases (also known as "The Pink Book"). The previous edition was published in 2012. Developed by CDC’s National Center for Immunization and Respiratory Diseases, this edition provides updated immunization and vaccine information to public health practitioners, healthcare providers, health educators, pharmacists, nurses, and others involved in administering vaccines. The following information is reprinted from the Public Health Foundation (PHF), the distributor of the print version of Epidemiology and Prevention of Vaccine-Preventable Diseases.
Current, credible, and comprehensive, "The Pink Book" contains information on each vaccine-preventable disease and delivers immunization providers with the latest information on:
Back to top
Check out IAC’s series of vaccine summaries for patients and parents
IAC wants to remind readers that we offer a series of easy-to-read summaries on all routine vaccines for patients and parents. Please review them to see if they might be of help to you in your work setting.Easy-to-read Vaccine Summaries for Parents
Use these one-page handouts to teach parents about the dangers of vaccine-preventable diseases and the value of vaccination.
Easy-to-read Vaccine Summaries for Teens and Adults
IAC's series of one-page, easy-to-read handouts that emphasize the dangers of the vaccine-preventable diseases and the importance of vaccination.
OFFICIAL RELEASES AND ANNOUNCEMENTS
CDC issues updated interim infection prevention and control recommendations for hospitalized patients with Middle East Respiratory Syndrome Coronavirus
CDC recently posted an update of its July 2014 guidance, Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), which highlighted the key infection control recommendations including standard, contact, and airborne precautions. The updated guidance continues to recommend standard, contact, and airborne precautions. In addition, it emphasizes additional elements of infection prevention and control programs that should be in place to prevent the transmission of any infectious agents including respiratory pathogens such as MERS-CoV in healthcare settings.
Medical Assistants Resources and Training on Immunization releases newsletter that focuses on HPV vaccination
Medical Assistants Resources and Training on Immunization (MARTi) is an organization that provides excellent immunization-related information and links to training opportunities for medical assistants. MARTi just released a newsletter on HPV vaccination that includes basic information and links to additional resources.
MARTi is funded through a cooperative agreement between CDC and the Association for Prevention Teaching and Research (APTR).
Visit the MARTi website at www.marti-us.org and be sure to recommend it to the medical assistants with whom you work and all others who administer vaccines!
Now available! IAC's sturdy laminated versions of the 2015 U.S. child/teen immunization schedule and the 2015 U.S. adult immunization schedule—order a supply for your healthcare setting today!
IAC's laminated versions of the 2015 U.S. child/teen immunization schedule and the 2015 U.S. adult immunization schedule are covered with a tough, washable coating; they will stand up to a year's worth of use in every area of your healthcare setting where immunizations are given. The child and adolescent schedule has eight pages (i.e., four double-sided pages) and is folded to measure 8.5" x 11". The adult immunization schedule has six pages (i.e., three double-sided pages) and is folded to measure 8.5" x 11".
Laminated schedules are printed in color for easy reading, come complete with essential tables and footnotes, and include contraindications and precautions—a feature that will help you make an on-the-spot determination about the safety of vaccinating patients of any age.
1–4 copies: $7.50 each
5–19 copies: $5.50 each
20–99 copies: $4.50 each
100–499 copies: $4.00 each
500–999 copies: $3.50 each
For quotes on customizing or placing orders for 1,000 copies or more, call (651) 647-9009 or email email@example.com.
You can access specific information on both schedules, view images of both, order online, or download an order form at the Shop IAC: Laminated Schedules web page.
Back to top
IAC makes available The Vaccine Handbook: A Practical Guide for Clinicians, a.k.a. "The Purple Book," by Dr. Gary Marshall
The Vaccine Handbook: A Practical Guide for Clinicians (“The Purple Book,” 2015, 560 pages) is a uniquely comprehensive source of practical, up-to-date information for vaccine providers and educators. Its author, Gary S. Marshall, MD, has drawn together the latest vaccine science and guidance into a concise, user-friendly, practical resource for the private office, public health clinic, academic medical center, and hospital.
IAC Executive Director Deborah Wexler, MD, is enthusiastic about helping get this book circulated as widely as possible. “During more than 20 years in the field of immunization education, I have not seen a book that is so brimming with state-of-the-science vaccine information,” she states. "This book belongs in the hands of every medical student, physician-in-training, doctor, nursing student, and nurse who provides vaccines to patients.”
The Vaccine Handbook provides:
Gary Marshall, MD, is professor of pediatrics at the University of Louisville School of Medicine in Kentucky, where he serves as chief of the division of pediatric infectious diseases and director of the Pediatric Clinical Trials Unit. In addition to being a busy clinician, he is nationally known for his work in the areas of vaccine research, advocacy, and education.
The newly released fifth edition of this invaluable guide is now available on IAC’s website at www.immunize.org/vaccine-handbook.
The price of the handbook is $29.95 each, plus shipping charges. Discount pricing is available for more than 10 copies. Order copies for your staff or for distribution at an upcoming conference.
Quantity Discount Pricing
Order your copy today! Back to top
JOURNAL ARTICLES AND NEWSLETTERS
CDC and WHO report on measles elimination in the Southeast Asia Region in this week's MMWR and Weekly Epidemiological Report, respectively
CDC published Progress Toward Measles Elimination—Southeast Asia Region, 2003–2013 in the June 12 issue of MMWR (pages 613–617). On the same day, WHO's Weekly Epidemiological Record published a similar article titled Progress towards measles elimination—Southeast Asia Region, 2003–2013. A summary of the MMWR article made available to the press by CDC is reprinted below.
In 2013, after rigorous prior consultations, the 66th session of the Regional Committee of the World Health Organization (WHO) Southeast Asia Region (SEAR) adopted the goal of measles elimination and CRS control by 2020. This report updates previous reports and summarizes progress toward measles elimination in SEAR during 2003–2013. Coverage with the first dose of a measles-containing vaccine (MCV1) increased from 67 percent to 78 percent and an estimated 286 million children (93 percent of the target) were vaccinated in SIAs. Measles incidence decreased 73 percent, from 59 to 16 cases per million population and estimated measles deaths decreased 63 percent.
EDUCATION AND TRAINING
Join CDC for a June 26 webinar on topics related to adolescent immunization
On June 26 at 12:00 p.m. (ET), CDC will sponsor its next #PreteenVaxScene webinar.
Back to top
Reminder: CDC's Epidemiology & Prevention of Vaccine-Preventable Diseases course to be held in Tacoma, Washington, on September 16–17
The State of Washington's immunization coalition, WithinReach, will sponsor CDC's live two-day Epidemiology & Prevention of Vaccine-Preventable Diseases course (also known as the "Pink Book" course) on September 16–17, in Tacoma, Washington. The course provides a comprehensive review of immunizations and the diseases they prevent. Continuing education credits are available. Additionally, a selection of pre-course workshops will be offered on September 15, with topics including HPV, vaccine hesitancy, and the Washington State Immunization Information System.
CONFERENCES AND MEETINGS
Agenda for June ACIP meeting available; listen to the meeting if you are unable to attend
CDC has released a new draft agenda for the next Advisory Committee on Immunization Practices (ACIP) meeting, which will be held June 24–25 at CDC's Clifton Road campus in Atlanta. Registration is now closed for attending this meeting in person, but interested individuals can listen to the meeting live. Registration is not required to listen to the meeting; the call-in information page is listed below. The live meeting recording and presenter slides are always made available online after the meeting as well.
ASK THE EXPERTS
Question of the Week
An 8-year-old child received three doses of oral polio vaccine before his first birthday. Should he receive an additional dose of inactivated poliovirus vaccine (IPV)?
Yes. This patient should receive a dose of IPV now. The final dose of the polio series should be received on or after the fourth birthday.
About IAC's Question of the Week
Each week, IAC Express highlights a new, topical, or important-to-reiterate Q&A. This feature is a cooperative venture between IAC and CDC. William L. Atkinson, MD, MPH, IAC's associate director for immunization education, chooses a new Q&A to feature every week from a set of Q&As prepared by experts at CDC’s National Center for Immunization and Respiratory Diseases.
We hope you enjoy this new feature and find it helpful when dealing with difficult real-life scenarios in your vaccination practice. Please encourage your healthcare professional colleagues to sign up to receive IAC Express at www.immunize.org/subscribe.
If you have a question for the CDC immunization experts, you can email them directly at firstname.lastname@example.org. There is no charge for this service.
IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer
Editor-in-ChiefKelly L. Moore, MD, MPH
Managing EditorJohn D. Grabenstein, RPh, PhD
Associate EditorSharon G. Humiston, MD, MPH
Writer/Publication CoordinatorTaryn Chapman, MS
Courtnay Londo, MA
Style and Copy EditorMarian Deegan, JD
Web Edition ManagersArkady Shakhnovich
Contributing WriterLaurel H. Wood, MPA
Technical ReviewerKayla Ohlde